JP Morgan Reinstates Neutral on BioCryst Pharma, Announces $12 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 69.0%

Neg 0% Neu 69% Pos 0%

JP Morgan analyst Jessica Fye reinstates BioCryst Pharma (NASDAQ:BCRX) with a Neutral and announces $12 price target.

Comments

No comments yet. Be the first!